BASEL LIFE 2019

9–12 September 2019

Congress Center Basel
Switzerland

Biotherapeutics

Date

Tuesday 10, September 2019

Chairs

Thomas Huber (Novartis, Switzerland)
Stefan Weigand (Roche, Switzerland)
Renè Assenberg (Janssen Biologics, Netherlands)

Abstract:

Disruptive innovations are driving future biotherapeutics to become more personalized, cost-effective and efficacious. The biotherapeutics are shifting from classical monoclonal antibodies towards more complex modalities, such as engineered antibodies, multi-specific antibodies, cell and gene therapies. The 2019 biotherapeutics forum discusses technology trends and developments required to progress current and future drug modalities from concepts to the market.

 

 

Tuesday, 10 September 2019

10.00 – 16.30

10.00
Fusion Proteins: Design principles and consequences for manufacturing
Dr. Stefan Schmidt (Bioatrium Visp, CH)

10.30
Challenges in CMC development of bispecific antibodies
Dr. Christian Cimander (GenMab, Copenhagen, DK)

11.00
Break

11.30
Master Checkpoint Cbl-b Inhibition: Ambulatory siRNA-based Autologous Cell Therapy for Cancer
Dr. Anderson Gaweco (Apeiron, Vienna, AT)

12.00
Gene Therapy CMC
Dr. Diane Blumenthal (Spark Therapeutics, Phiadelphia, USA)

12.30
Lunch Break & Industry Symposia

14.00
Therapeutic Use of Genome Editing – A Vision for the Future
Dr. Lorenz Mayr (GE Healthcare, Little Chalfont, UK)

14.30
mRNA as a platform technology ideally suited for individualized therapeutics
Dr. Andreas Kuhn (BioNtech, Mainz, DE)

15.00
Break

15.30
CMC opportunities and challenges in bringing new, complex modalities to the patient
Eileen Brett (Janssen Pharmaceuticals, Phiadelphia, USA)       

16.00
Co-expression of IgG-like bispecifics for efficient manufacturing
Dr. Michael Bardroff (Novartis, Basel, CH)

Room Samarkand